Transaction DateRecipientSharesTypePriceValue
24th September 2020Management Inc. Opaleye100,000Open or private purchase$16.87$1,687,000.00
24th September 2020Management Inc. Opaleye200,000Open or private purchase$16.87$3,374,000.00
22nd September 2020Blaine Davis1,481Open or private purchase$16.91$25,037.79
18th September 2020John Gordon Freund400,000Open or private sale$12.00$4,800,000.00
14th September 2020Randall Marshall474Open or private sale$20.00$9,480.00
14th September 2020Randall Marshall2,080Open or private sale$19.26$40,060.80
11th September 2020John Gordon Freund500,000Open or private sale$10.00$5,000,000.00
10th September 2020Randall Marshall239Open or private sale$18.00$4,302.00
9th September 2020Randall Marshall5,309Open or private sale$18.10$96,092.90
9th September 2020Management Inc. Opaleye45,000Open or private purchase$3.47$156,100.50
Proteon Therapeutics
Proteon Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Proteon Therapeutics, Inc. engages in the research and development of biopharmaceutical products. It produces and commercializes vonapanitase for the treatment of renal and vascular disease. The company was founded by F. Nicholas Franano and William P. Whitaker in 2001.

Ticker: PRTO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1359931
Employees: 17
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags